View Financial HealthArvee Laboratories (India) 배당 및 자사주 매입배당 기준 점검 0/6Arvee Laboratories (India) 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.공시 • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.공시 • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Additional Director Shalini Jalan was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.15 (vs ₹0.85 in 1Q 2025)First quarter 2026 results: EPS: ₹0.15 (down from ₹0.85 in 1Q 2025). Revenue: ₹76.5m (down 28% from 1Q 2025). Net income: ₹1.69m (down 82% from 1Q 2025). Profit margin: 2.2% (down from 8.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.공시 • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025.New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹391m revenue, or US$4.6m). Market cap is less than US$100m (₹1.95b market cap, or US$22.8m).Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹150, the stock trades at a trailing P/E ratio of 75.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 92% over the past three years.Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.22 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (down from ₹0.22 in 3Q 2024). Revenue: ₹89.1m (up 16% from 3Q 2024). Net income: ₹1.55m (down 35% from 3Q 2024). Profit margin: 1.7% (down from 3.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.분석 기사 • Jan 12Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 28%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 28% after a relatively good...New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 2.5% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₹370m revenue, or US$4.4m). Market cap is less than US$100m (₹2.49b market cap, or US$29.4m).분석 기사 • Nov 21Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 25%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 25% after a relatively good...Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.89 (vs ₹0.19 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.89 (up from ₹0.19 in 2Q 2024). Revenue: ₹126.8m (up 42% from 2Q 2024). Net income: ₹9.81m (up 366% from 2Q 2024). Profit margin: 7.7% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.85 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹0.85 (up from ₹0.44 in 1Q 2024). Revenue: ₹107.1m (up 41% from 1Q 2024). Net income: ₹9.42m (up 93% from 1Q 2024). Profit margin: 8.8% (up from 6.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.공시 • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024, at 11:30 Indian Standard Time.공시 • Mar 27Arvee Laboratories (India) Ltd. Announces Resignation of Mr. Dipen Dalal as Independent DirectorArvee Laboratories (India) Ltd. informed that Mr. Dipen Dalal, - Independent Director of the company has tendered his resignation vide letter dated March 26, 2024. He will be cease to be a Director of the company with effect from 26th March, 2024.Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.84 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.22 (down from ₹0.84 in 3Q 2023). Revenue: ₹78.9m (down 52% from 3Q 2023). Net income: ₹2.38m (down 74% from 3Q 2023). Profit margin: 3.0% (down from 5.7% in 3Q 2023). The decrease in margin was driven by lower revenue.New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Revenue is less than US$5m (₹369m revenue, or US$4.4m). Market cap is less than US$100m (₹1.39b market cap, or US$16.7m).Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹1.86 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.19 (down from ₹1.86 in 2Q 2023). Revenue: ₹90.0m (down 60% from 2Q 2023). Net income: ₹2.11m (down 90% from 2Q 2023). Profit margin: 2.3% (down from 9.0% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.공시 • Aug 26+ 3 more updatesArvee Laboratories (India) Ltd. to Report Q4, 2024 Results on May 30, 2024Arvee Laboratories (India) Ltd. announced that they will report Q4, 2024 results on May 30, 2024Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹1.03 in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (down from ₹1.03 in 1Q 2023). Revenue: ₹76.9m (down 58% from 1Q 2023). Net income: ₹4.87m (down 57% from 1Q 2023). Profit margin: 6.3% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Aug 08Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹124, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 519% over the past three years.Reported Earnings • May 08Full year 2023 earnings released: EPS: ₹4.43 (vs ₹2.34 in FY 2022)Full year 2023 results: EPS: ₹4.43 (up from ₹2.34 in FY 2022). Revenue: ₹697.9m (up 73% from FY 2022). Net income: ₹41.2m (up 60% from FY 2022). Profit margin: 5.9% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹106, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 7.3% over the past year.분석 기사 • Apr 13Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹0.84 (vs ₹0.48 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.84 (up from ₹0.48 in 3Q 2022). Revenue: ₹162.5m (up 106% from 3Q 2022). Net income: ₹9.21m (up 73% from 3Q 2022). Profit margin: 5.7% (down from 6.8% in 3Q 2022). The decrease in margin was driven by higher expenses.분석 기사 • Dec 22Do Arvee Laboratories (India)'s (NSE:ARVEE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹160, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 97% over the past year.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹115, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 44% over the past year.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year.분석 기사 • Sep 16We Ran A Stock Scan For Earnings Growth And Arvee Laboratories (India) (NSE:ARVEE) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Aug 03First quarter 2023 earnings released: EPS: ₹1.03 (vs ₹0.48 in 1Q 2022)First quarter 2023 results: EPS: ₹1.03 (up from ₹0.48 in 1Q 2022). Revenue: ₹182.0m (up 101% from 1Q 2022). Net income: ₹11.4m (up 116% from 1Q 2022). Profit margin: 6.3% (up from 5.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jul 14Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022, at 11:30 Indian Standard Time. Location: Registered Office of the Company situated at 403, Entice Nr. Jayantilal Park BRTS, Iskcon-Bopal Road Ahemdabad Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2022 and Statement of Profit and Loss and Cash Flow Statement for the year ended on 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto; to reappoint Mr. Shalin Bharatbhai Chokshi a Director of the Company who retires by rotation and being eligible offers himself for re-appointment; to appoint statutory auditor of the Company.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹90.15, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 206% over the past three years.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹66.20, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 124% over the past three years.Reported Earnings • May 28Full year 2022 earnings released: EPS: ₹2.34 (vs ₹2.43 in FY 2021)Full year 2022 results: EPS: ₹2.34 (down from ₹2.43 in FY 2021). Revenue: ₹407.9m (down 14% from FY 2021). Net income: ₹25.7m (down 3.9% from FY 2021). Profit margin: 6.3% (up from 5.7% in FY 2021). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹88.80, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 50% over the past year.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹92.90, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 238% over the past three years.Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.48 (down from ₹1.39 in 3Q 2021). Revenue: ₹79.0m (down 60% from 3Q 2021). Net income: ₹5.34m (down 65% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 20x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹74.90, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 158% over the past three years.Executive Departure • Sep 23Independent Director Paragbhai Shah has left the companyOn the 16th of September, Paragbhai Shah's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Paragbhai's name. Paragbhai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹89.00, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.분석 기사 • Aug 13Subdued Growth No Barrier To Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) PriceArvee Laboratories (India) Ltd.'s ( NSE:ARVEE ) price-to-earnings (or "P/E") ratio of 42.6x might make it look like a...Reported Earnings • Jul 18First quarter 2022 earnings released: EPS ₹0.48 (vs ₹0.91 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹91.2m (up 1.0% from 1Q 2021). Net income: ₹5.29m (up 5.2% from 1Q 2021). Profit margin: 5.8% (up from 5.6% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jun 20Full year 2021 earnings released: EPS ₹2.43 (vs ₹2.02 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹479.6m (up 5.6% from FY 2020). Net income: ₹26.8m (up 20% from FY 2020). Profit margin: 5.6% (up from 4.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹122, the stock trades at a trailing P/E ratio of 60.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹159, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years.분석 기사 • Apr 19Calculating The Intrinsic Value Of Arvee Laboratories (India) Ltd. (NSE:ARVEE)Today we will run through one way of estimating the intrinsic value of Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) by...지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ARVEE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ARVEE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Arvee Laboratories (India) 배당 수익률 vs 시장ARVEE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARVEE)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Chemicals)0.8%분석가 예측 (ARVEE) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARVEE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARVEE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARVEE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ARVEE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/08 18:03종가2026/07/08 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Arvee Laboratories (India) Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 21Full year 2026 earnings released: EPS: ₹2.29 (vs ₹1.95 in FY 2025)Full year 2026 results: EPS: ₹2.29 (up from ₹1.95 in FY 2025). Revenue: ₹322.0m (down 16% from FY 2025). Net income: ₹25.3m (up 18% from FY 2025). Profit margin: 7.8% (up from 5.6% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
공시 • May 05Arvee Laboratories (India) Ltd. to Report Fiscal Year 2026 Results on May 18, 2026Arvee Laboratories (India) Ltd. announced that they will report fiscal year 2026 results on May 18, 2026
Reported Earnings • Feb 17Third quarter 2026 earnings released: EPS: ₹1.66 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.66 (up from ₹0.14 in 3Q 2025). Revenue: ₹97.8m (up 9.8% from 3Q 2025). Net income: ₹18.3m (up ₹16.7m from 3Q 2025). Profit margin: 19% (up from 1.7% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
공시 • Feb 06Arvee Laboratories (India) Ltd. to Report Q3, 2026 Results on Feb 13, 2026Arvee Laboratories (India) Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹263m revenue, or US$2.9m). Market cap is less than US$100m (₹2.18b market cap, or US$24.2m).
New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 6.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹264m revenue, or US$3.0m). Market cap is less than US$100m (₹1.85b market cap, or US$20.8m).
Board Change • Sep 23Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Additional Director Shalini Jalan was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.15 (vs ₹0.85 in 1Q 2025)First quarter 2026 results: EPS: ₹0.15 (down from ₹0.85 in 1Q 2025). Revenue: ₹76.5m (down 28% from 1Q 2025). Net income: ₹1.69m (down 82% from 1Q 2025). Profit margin: 2.2% (down from 8.9% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
공시 • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 24, 2025.
New Risk • Jun 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹391m revenue, or US$4.6m). Market cap is less than US$100m (₹1.95b market cap, or US$22.8m).
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹150, the stock trades at a trailing P/E ratio of 75.3x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 92% over the past three years.
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.22 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (down from ₹0.22 in 3Q 2024). Revenue: ₹89.1m (up 16% from 3Q 2024). Net income: ₹1.55m (down 35% from 3Q 2024). Profit margin: 1.7% (down from 3.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
분석 기사 • Jan 12Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 28%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 28% after a relatively good...
New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 2.5% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₹370m revenue, or US$4.4m). Market cap is less than US$100m (₹2.49b market cap, or US$29.4m).
분석 기사 • Nov 21Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) Popularity With Investors Under Threat As Stock Sinks 25%Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) shares have had a horrible month, losing 25% after a relatively good...
Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹0.89 (vs ₹0.19 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.89 (up from ₹0.19 in 2Q 2024). Revenue: ₹126.8m (up 42% from 2Q 2024). Net income: ₹9.81m (up 366% from 2Q 2024). Profit margin: 7.7% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹0.85 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹0.85 (up from ₹0.44 in 1Q 2024). Revenue: ₹107.1m (up 41% from 1Q 2024). Net income: ₹9.42m (up 93% from 1Q 2024). Profit margin: 8.8% (up from 6.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
공시 • Aug 13Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024Arvee Laboratories (India) Ltd., Annual General Meeting, Sep 28, 2024, at 11:30 Indian Standard Time.
공시 • Mar 27Arvee Laboratories (India) Ltd. Announces Resignation of Mr. Dipen Dalal as Independent DirectorArvee Laboratories (India) Ltd. informed that Mr. Dipen Dalal, - Independent Director of the company has tendered his resignation vide letter dated March 26, 2024. He will be cease to be a Director of the company with effect from 26th March, 2024.
Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.84 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.22 (down from ₹0.84 in 3Q 2023). Revenue: ₹78.9m (down 52% from 3Q 2023). Net income: ₹2.38m (down 74% from 3Q 2023). Profit margin: 3.0% (down from 5.7% in 3Q 2023). The decrease in margin was driven by lower revenue.
New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Revenue is less than US$5m (₹369m revenue, or US$4.4m). Market cap is less than US$100m (₹1.39b market cap, or US$16.7m).
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹1.86 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.19 (down from ₹1.86 in 2Q 2023). Revenue: ₹90.0m (down 60% from 2Q 2023). Net income: ₹2.11m (down 90% from 2Q 2023). Profit margin: 2.3% (down from 9.0% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Aug 26+ 3 more updatesArvee Laboratories (India) Ltd. to Report Q4, 2024 Results on May 30, 2024Arvee Laboratories (India) Ltd. announced that they will report Q4, 2024 results on May 30, 2024
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹1.03 in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (down from ₹1.03 in 1Q 2023). Revenue: ₹76.9m (down 58% from 1Q 2023). Net income: ₹4.87m (down 57% from 1Q 2023). Profit margin: 6.3% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Aug 08Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹124, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 519% over the past three years.
Reported Earnings • May 08Full year 2023 earnings released: EPS: ₹4.43 (vs ₹2.34 in FY 2022)Full year 2023 results: EPS: ₹4.43 (up from ₹2.34 in FY 2022). Revenue: ₹697.9m (up 73% from FY 2022). Net income: ₹41.2m (up 60% from FY 2022). Profit margin: 5.9% (down from 6.4% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Apr 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹106, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 7.3% over the past year.
분석 기사 • Apr 13Here's Why We Think Arvee Laboratories (India) (NSE:ARVEE) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹108, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.
Reported Earnings • Feb 05Third quarter 2023 earnings released: EPS: ₹0.84 (vs ₹0.48 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.84 (up from ₹0.48 in 3Q 2022). Revenue: ₹162.5m (up 106% from 3Q 2022). Net income: ₹9.21m (up 73% from 3Q 2022). Profit margin: 5.7% (down from 6.8% in 3Q 2022). The decrease in margin was driven by higher expenses.
분석 기사 • Dec 22Do Arvee Laboratories (India)'s (NSE:ARVEE) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹160, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 97% over the past year.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹115, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 44% over the past year.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹1.86 (vs ₹0.66 in 2Q 2022)Second quarter 2023 results: EPS: ₹1.86 (up from ₹0.66 in 2Q 2022). Revenue: ₹228.0m (up 113% from 2Q 2022). Net income: ₹20.5m (up 182% from 2Q 2022). Profit margin: 9.0% (up from 6.8% in 2Q 2022). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹101, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year.
분석 기사 • Sep 16We Ran A Stock Scan For Earnings Growth And Arvee Laboratories (India) (NSE:ARVEE) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Aug 03First quarter 2023 earnings released: EPS: ₹1.03 (vs ₹0.48 in 1Q 2022)First quarter 2023 results: EPS: ₹1.03 (up from ₹0.48 in 1Q 2022). Revenue: ₹182.0m (up 101% from 1Q 2022). Net income: ₹11.4m (up 116% from 1Q 2022). Profit margin: 6.3% (up from 5.8% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jul 14Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022Arvee Laboratories (India) Ltd., Annual General Meeting, Aug 04, 2022, at 11:30 Indian Standard Time. Location: Registered Office of the Company situated at 403, Entice Nr. Jayantilal Park BRTS, Iskcon-Bopal Road Ahemdabad Gujarat India Agenda: To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2022 and Statement of Profit and Loss and Cash Flow Statement for the year ended on 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon and documents annexed thereto; to reappoint Mr. Shalin Bharatbhai Chokshi a Director of the Company who retires by rotation and being eligible offers himself for re-appointment; to appoint statutory auditor of the Company.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹90.15, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 206% over the past three years.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to ₹66.20, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 124% over the past three years.
Reported Earnings • May 28Full year 2022 earnings released: EPS: ₹2.34 (vs ₹2.43 in FY 2021)Full year 2022 results: EPS: ₹2.34 (down from ₹2.43 in FY 2021). Revenue: ₹407.9m (down 14% from FY 2021). Net income: ₹25.7m (down 3.9% from FY 2021). Profit margin: 6.3% (up from 5.7% in FY 2021). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹88.80, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 50% over the past year.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹92.90, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 238% over the past three years.
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.48 (down from ₹1.39 in 3Q 2021). Revenue: ₹79.0m (down 60% from 3Q 2021). Net income: ₹5.34m (down 65% from 3Q 2021). Profit margin: 6.8% (down from 7.7% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 20x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹74.90, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 158% over the past three years.
Executive Departure • Sep 23Independent Director Paragbhai Shah has left the companyOn the 16th of September, Paragbhai Shah's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Paragbhai's name. Paragbhai is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.33 years.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹89.00, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.
분석 기사 • Aug 13Subdued Growth No Barrier To Arvee Laboratories (India) Ltd.'s (NSE:ARVEE) PriceArvee Laboratories (India) Ltd.'s ( NSE:ARVEE ) price-to-earnings (or "P/E") ratio of 42.6x might make it look like a...
Reported Earnings • Jul 18First quarter 2022 earnings released: EPS ₹0.48 (vs ₹0.91 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹91.2m (up 1.0% from 1Q 2021). Net income: ₹5.29m (up 5.2% from 1Q 2021). Profit margin: 5.8% (up from 5.6% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jun 20Full year 2021 earnings released: EPS ₹2.43 (vs ₹2.02 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹479.6m (up 5.6% from FY 2020). Net income: ₹26.8m (up 20% from FY 2020). Profit margin: 5.6% (up from 4.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹122, the stock trades at a trailing P/E ratio of 60.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 359% over the past three years.
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to ₹159, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years.
분석 기사 • Apr 19Calculating The Intrinsic Value Of Arvee Laboratories (India) Ltd. (NSE:ARVEE)Today we will run through one way of estimating the intrinsic value of Arvee Laboratories (India) Ltd. ( NSE:ARVEE ) by...